Phase II trial with Aviscumine (CY-503): Metastatic Melanoma

CYTAVIS BioPharma is currently conducting a phase II trial with Aviscumine (CY-503) in patients with metastatic melanoma (stage IV).

01.04.2009 (12:09) by Administrator